Writing contest · Deadline February 15, 2027

MediDebate Writing Competition 2026

High school students · 400–800 words · $250 first prize · Top 30% featured

How to enter

Now accepting writers 5 high school students per state Deadline Nov 19, 2026

Submit your article

The Hidden War Against Rare Childhood Cancer

Learning that your child has cancer can be devastating, but finding out how rare their type can be is more worrying.

Unfortunately, many families will have to deal with that uncertainty. The National Cancer Institute (NCI) states that around 11% of childhood cancers are extremely rare. This can be a barrier to developing treatments due to the small number of patients involved in clinical trials.

This leads to a problem. Should research be focused on the most common cancers or those with the least amount of treatment options?

Arguments For Focusing On Common Cancers

There is a limited amount of funding for research. By investing in one disease, you may be taking away funds from another.

People who support focusing on common cancers argue that by focusing on diseases that affect more people, you can help more people, as more people will benefit from medical advances. Larger clinical trials give more accurate data, which can be used to work on treatments and lead
to faster scientific development.

It can not necessarily be seen as unfair to focus on common diseases, as it can be a challenging choice to make.

The Case for Rare Pediatric Cancers


However, should children have a different chance of getting effective treatments based on how
rare their cancer is?

Rare childhood cancers can cause issues outside of funding. Due to small numbers of patients, it can be difficult to run trials. There are location issues, as some families can not attend
specialist centers.

In June 2026, the American Society of Clinical Oncology (ASCO) recommended increasing eligibility criteria for pediatric trials, increasing funding, and improving access in the community.

The Childhood Cancer Data Initiative at the NCI is collecting data between institutions to allow researchers to gain a better understanding of rare cancers and create future studies.

This shows that rarity does not necessarily mean that they will not receive the scientific attention
they deserve.

My Verdict

Both sides have valid points. Funding common cancers can help large numbers of people; however, rare childhood diseases can leave the most vulnerable without any options.

A balance can be made using a research system that allows both sides to be taken into consideration. This can be achieved through collaboration, shared research, more funding, and
more accessible trials.

In medicine, no one should be valued less due to the rarity of their disease.